N-(4-氰基-3-甲基-1,2-噻唑-5-基)丁酰胺 | 162702-06-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-(4-氰基-3-甲基-1,2-噻唑-5-基)丁酰胺
• 英文名称: N-(4-cyano-3-methyl-1,2-thiazol-5-yl)butanamide
• 英文别名: N-(4-cyano-3-methyl-isothiazol-5-yl)-butyramide
• CAS: 162702-06-9
• 化学式: C₉H₁₁N₃OS
• 分子量: 209.272
• InChiKey: AYPMWVMOQSFAIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  94
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-氰基-3-甲基-1,2-噻唑-5-基)丁酰胺 在 ammonium hydroxide 、 双氧水 、 溴 、 sodium acetate 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 52.83h， 生成 tert-butyl N-[3-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)propyl-(4-methylbenzoyl)amino]propyl]carbamate
  参考文献：
  名称：

  Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent

  摘要：

  Structure activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.

  DOI：

  10.1021/jm200629m
• 作为产物：
  描述：

  2-(1-乙氧基亚乙基)丙二腈 在 硫化氢 、 氨 、 双氧水 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 苯 为溶剂， 反应 36.67h， 生成 N-(4-氰基-3-甲基-1,2-噻唑-5-基)丁酰胺
  参考文献：
  名称：

  Discovery of (+)-N-(3-Aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a Kinesin Spindle Protein Inhibitor and Potential Anticancer Agent

  摘要：

  Structure activity relationship analysis identified (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), from a series of novel kinesin spindle protein (KSP) inhibitors, as exhibiting both excellent biochemical potency and pharmaceutical properties suitable for clinical development. The selected compound arrested cells in mitosis leading to the formation of the monopolar spindle phenotype characteristic of KSP inhibition and induction of cellular death. A favorable pharmacokinetic profile and notable in vivo efficacy supported the selection of this compound as a clinical candidate for the treatment of cancer.

  DOI：

  10.1021/jm200629m

文献信息

• Selected fused heterocyclics and uses thereof
  申请人：Aquila Brian

  公开号：US20060041128A1

  公开（公告）日：2006-02-23

  This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

  这项发明涉及具有结构式（I）的新化合物，以及它们的药物组合物和使用方法。这些新化合物提供了癌症的治疗或预防。
• [EN] NOVEL FUSED HETEROCYCLES AND USES THEREOF<br/>[FR] NOUVEAUX HETEROCYCLES FUSIONNES ET LEURS UTILISATIONS
  申请人：ASTRAZENECA AB

  公开号：WO2004078758A1

  公开（公告）日：2004-09-16

  This invention relates to novel compounds having the formula (I) (a chemical formula should be inserted here - please see paper copy enclosed herewith) m = 0, 1, 2 n = 0, 1 (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

  这项发明涉及具有以下公式（I）的新化合物（此处应插入化学式 - 请参阅随附的纸质副本） m = 0, 1, 2 n = 0, 1 其中R1、R2、R3、R4、R5、R6、R7、R8和R9如规范中所定义，以及它们的药物组合物和使用方法。这些新化合物提供了癌症的治疗或预防。
• Enantiomers of selected fused heterocyclics and uses thereof
  申请人：Aquila Brian

  公开号：US20060041129A1

  公开（公告）日：2006-02-23

  This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

  本发明涉及具有结构式（I）的新化合物，以及它们的制药组合物和使用方法。这些新化合物提供了治疗或预防癌症的方法。
• Novel fused heterocycles and uses thereof
  申请人：Aquila Brian

  公开号：US20060063751A1

  公开（公告）日：2006-03-23

  This invention relates to novel compounds having the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined in the specification and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

  本发明涉及具有公式（I）的新化合物，其中R1，R2，R3，R4，R5，R6，R7，R8和R9如规范中所定义，并涉及它们的制药组合物和使用方法。这些新化合物提供了治疗或预防癌症的方法。
• Novel Fused Heterocycles and Uses Thereof
  申请人：Aquila Brian

  公开号：US20060270689A1

  公开（公告）日：2006-11-30

  This invention relates to novel compounds having the formula (I) (a chemical formula should be inserted here—please see paper copy enclosed herewith) m=0, 1, 2 n=0, 1 (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.

  本发明涉及具有以下公式（I）的新化合物（应在此处插入化学式-请参见随附的纸质副本）m = 0，1，2 n = 0，1（I）其中R1，R2，R3，R4，R5，R6，R7，R8和R9如规范所定义，并且涉及它们的药物组合物和使用方法。这些新化合物提供了治疗或预防癌症的方法。